Literature DB >> 1582980

Drug resistance in myeloma: mechanisms and approaches to circumvention.

W S Dalton1, S E Salmon.   

Abstract

Chemotherapy remains the mainstay in the treatment of multiple myeloma today. Despite improvements in survival and quality of life that can be attributed to advances in chemotherapeutic treatment, multiple myeloma remains an incurable disease. The development of drug resistance accounts for most treatment failures. Mechanisms of resistance for chemotherapeutic agents occur at the cellular level. Some of these mechanisms are unique for a given individual drug, whereas other mechanisms may confer resistance to a wide variety of agents. Important steps for improving treatment include investigating the resistance mechanisms, developing methods to identify drug-resistant cells, and preventing or circumventing drug resistance once it occurs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582980

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

Review 1.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.

Authors:  D S Siegel; X Zhang; R Feinman; T Teitz; A Zelenetz; V M Richon; R A Rifkind; P A Marks; J Michaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  Vincristine and oral etoposide in refractory multiple myeloma.

Authors:  R K Ganjoo; A Williams; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.